Código QR (código de barras bidimensional)

Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres

We assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, the median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support. The in-hospital mortality rate was 24%. These data advance our understand...

ver descrição completa

Na minha lista:
Principais autores: Ryan K. Shields, Emre Yücel, Vladimir Turzhitsky, Sanjay Merchant, Jae S. Min, Alexandre H. Watanabe
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2024-06-01
coleção:Journal of Global Antimicrobial Resistance
Assuntos:
Complicated urinary tract infections
Gram-negative infection
Hospital-acquired/ventilator-associated bacterial pneumonia
Imipenem/cilastatin/relebactam
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2213716524000559
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados